Skip to main content
Erschienen in: Tumor Biology 1/2012

01.02.2012 | Research Article

Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma

verfasst von: Wenjun Wang, Zhu-lin Yang, Jie-qiong Liu, Song Jiang, Xiong-ying Miao

Erschienen in: Tumor Biology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Gallbladder cancers (GBC) are associated with high disease-specific mortality rates because of no means of early detection and effective therapies. In this study, we investigated CD146 expression, microvessel densities, and lymph vessel densities in 108 adenocarcinomas, 15 gallbladder polyps, 35 chronic cholecystitis tissues, and 46 peritumoral tissues using immunohistochemistry. We demonstrated that positive CD146 expression, and average microvessel and lymph vessel counts in gallbladder adenocarcinomas were significantly higher than those in peritumoral tissues, polyps, and chronic cholecystitis (ps < 0.01). Positive CD146 expression, and average microvessel and lymph vessel counts were also significantly lower in cases with well-differentiated adenocarcinoma, maximal tumor diameter <2 cm, no metastasis of lymph node, and no invasion of regional tissues than in cases with poorly differentiated adenocarcinoma, maximal tumor diameter ≥2 cm, metastasis in lymph nodes, and invasion of regional tissues (p < 0.05 or p < 0.01). Univariate Kaplan–Meier analysis showed that increased expression of CD146 (p = 0.056), higher average microvessel counts (p < 0.05), and lymph vessel counts (p < 0.05) were associated with decreased overall survival. Multivariate Cox regression analysis showed that average microvessel and lymph vessel counts (ps < 0.05) were independent prognostic predictors in gallbladder adenocarcinoma. Our study suggested that the elevated expression of CD146, angiogenesis, and lymphangiogenesis might be closely related to progression, invasion, metastasis, and prognosis of gallbladder adenocarcinoma.
Literatur
1.
Zurück zum Zitat Jones RS. Carcinoma of the gallbladder. Surg Clin North Am. 1990;70:1419–28.PubMed Jones RS. Carcinoma of the gallbladder. Surg Clin North Am. 1990;70:1419–28.PubMed
2.
Zurück zum Zitat Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–90.PubMedCrossRef Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–90.PubMedCrossRef
3.
Zurück zum Zitat Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef
4.
Zurück zum Zitat Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef
5.
Zurück zum Zitat Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42:253–60.PubMedCrossRef Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010;42:253–60.PubMedCrossRef
6.
Zurück zum Zitat Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef
7.
Zurück zum Zitat Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef
8.
Zurück zum Zitat Maurya SK, Tewari M, Mishra RR. Genetic aberrations in gallbladder cancer. Surg Oncol. 2010; Sep 28. [Epub ahead of print] Maurya SK, Tewari M, Mishra RR. Genetic aberrations in gallbladder cancer. Surg Oncol. 2010; Sep 28. [Epub ahead of print]
9.
Zurück zum Zitat Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, et al. Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res. 2007;13:76–80.PubMedCrossRef Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, et al. Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res. 2007;13:76–80.PubMedCrossRef
11.
Zurück zum Zitat He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta. 2004;1654:3–12.PubMed He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta. 2004;1654:3–12.PubMed
12.
Zurück zum Zitat Delatorre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviors. Endocr Relat Cancer. 2006;13:934–44. Delatorre NG, Buley I, Wass JA, et al. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviors. Endocr Relat Cancer. 2006;13:934–44.
13.
Zurück zum Zitat Aldovinni D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. MCAM expression as marker of prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119:1920–6.CrossRef Aldovinni D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. MCAM expression as marker of prognosis in epithelial ovarian cancer. Int J Cancer. 2006;119:1920–6.CrossRef
14.
Zurück zum Zitat Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 2002;86:1566–77.PubMedCrossRef Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer. 2002;86:1566–77.PubMedCrossRef
15.
Zurück zum Zitat Beenken SW, Bland KI. Biomarkers for breast cancer. Minerva Chir. 2002;57:437–48.PubMed Beenken SW, Bland KI. Biomarkers for breast cancer. Minerva Chir. 2002;57:437–48.PubMed
16.
Zurück zum Zitat Legan M. New marker of angiogenesis CD105 (endoglin): diagnostic, prognostic and therapeutic role. Radiol Oncol. 2005;39:253–9. Legan M. New marker of angiogenesis CD105 (endoglin): diagnostic, prognostic and therapeutic role. Radiol Oncol. 2005;39:253–9.
17.
Zurück zum Zitat Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591–7.PubMedCrossRef Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591–7.PubMedCrossRef
18.
19.
Zurück zum Zitat Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009;13:1405–16.PubMedCrossRef Mumprecht V, Detmar M. Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009;13:1405–16.PubMedCrossRef
20.
Zurück zum Zitat Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s and a subset of angiosarcomas. Mod Pathol. 2002;15:434–40.PubMedCrossRef Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s and a subset of angiosarcomas. Mod Pathol. 2002;15:434–40.PubMedCrossRef
21.
Zurück zum Zitat Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Modern Pathol. 2005;18:105–10.CrossRef Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Modern Pathol. 2005;18:105–10.CrossRef
22.
Zurück zum Zitat Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1989;86:9891–5.PubMedCrossRef Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1989;86:9891–5.PubMedCrossRef
23.
Zurück zum Zitat Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta. 2009;1795:130–6.PubMed Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta. 2009;1795:130–6.PubMed
24.
Zurück zum Zitat Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and C-Met and with proteomic basal-like phenotype. Hum Pathol. 2007;38:830–41.PubMedCrossRef Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and C-Met and with proteomic basal-like phenotype. Hum Pathol. 2007;38:830–41.PubMedCrossRef
25.
Zurück zum Zitat Watson-Hurst K, Becker D. The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther. 2006;5:1375–82.PubMedCrossRef Watson-Hurst K, Becker D. The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther. 2006;5:1375–82.PubMedCrossRef
26.
Zurück zum Zitat Yang H, Wang S, Liu Z, Wu MH, McAlpine B, Ansel J, et al. Isolation and characterization of mouse MUC18 cDNA gene, and correlation of MUC18 expression in mouse melanoma cell lines with metastatic ability. Gene. 2001;265:133–45.PubMedCrossRef Yang H, Wang S, Liu Z, Wu MH, McAlpine B, Ansel J, et al. Isolation and characterization of mouse MUC18 cDNA gene, and correlation of MUC18 expression in mouse melanoma cell lines with metastatic ability. Gene. 2001;265:133–45.PubMedCrossRef
27.
Zurück zum Zitat Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef
28.
Zurück zum Zitat Yamagiwa H, Tomiyama H, Yoshimura H. Histogenesis of carcinoma of gallbladder. Histological study of serial sections of 1000 cases of resected gallbladder. Rinsho Byori. 1986;34:475–80.PubMed Yamagiwa H, Tomiyama H, Yoshimura H. Histogenesis of carcinoma of gallbladder. Histological study of serial sections of 1000 cases of resected gallbladder. Rinsho Byori. 1986;34:475–80.PubMed
29.
Zurück zum Zitat Dowling GP, Kelly JK. The histogenesis of adenocarcinoma of the gallbladder. Cancer. 1986;58:1702–8.PubMedCrossRef Dowling GP, Kelly JK. The histogenesis of adenocarcinoma of the gallbladder. Cancer. 1986;58:1702–8.PubMedCrossRef
30.
Zurück zum Zitat Sanada Y, Yoshida K, Ohara M, Tsutani Y. Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res. 2007;13:105–13.PubMedCrossRef Sanada Y, Yoshida K, Ohara M, Tsutani Y. Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res. 2007;13:105–13.PubMedCrossRef
31.
Zurück zum Zitat Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res. 2007;13:326–35.PubMedCrossRef Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res. 2007;13:326–35.PubMedCrossRef
32.
Zurück zum Zitat Tucek S, Tomasek J, Halámkova J. Bile duct malignancies. Klin Onkol. 2010;23:231–41.PubMed Tucek S, Tomasek J, Halámkova J. Bile duct malignancies. Klin Onkol. 2010;23:231–41.PubMed
33.
34.
Zurück zum Zitat Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.PubMedCrossRef Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.PubMedCrossRef
35.
Zurück zum Zitat Sugawara Y, Makuuchi M, Harihara Y, Noie T, Inoue K, Kubota K, et al. Tumor angiogenesis in gallbladder carcinoma. Hepatogastroenterology. 1999;46:1682–6.PubMed Sugawara Y, Makuuchi M, Harihara Y, Noie T, Inoue K, Kubota K, et al. Tumor angiogenesis in gallbladder carcinoma. Hepatogastroenterology. 1999;46:1682–6.PubMed
36.
Zurück zum Zitat Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am J Clin Oncol. 2002;25:38–41.PubMedCrossRef Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am J Clin Oncol. 2002;25:38–41.PubMedCrossRef
37.
Zurück zum Zitat Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.PubMedCrossRef Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.PubMedCrossRef
38.
Zurück zum Zitat Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta. 2008;1786:87–104.PubMed Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta. 2008;1786:87–104.PubMed
39.
Zurück zum Zitat Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol. 2005;18:97–104.PubMedCrossRef Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol. 2005;18:97–104.PubMedCrossRef
40.
Zurück zum Zitat Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057–67.PubMedCrossRef Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057–67.PubMedCrossRef
41.
Zurück zum Zitat Hardavella G, Arkoumani E, Dalavanga Y, Galanis P, Agnantis NJ, Constantopoulos S, et al. Prognostic impact of lymphangiogenesis and lymphatic invasion (CD105 expression) in small cell lung carcinoma. Anticancer Res. 2008;28:343–7.PubMed Hardavella G, Arkoumani E, Dalavanga Y, Galanis P, Agnantis NJ, Constantopoulos S, et al. Prognostic impact of lymphangiogenesis and lymphatic invasion (CD105 expression) in small cell lung carcinoma. Anticancer Res. 2008;28:343–7.PubMed
42.
Zurück zum Zitat Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, Wiedenmann B, et al. Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:791–9.PubMedCrossRef Thelen A, Scholz A, Benckert C, Weichert W, Dietz E, Wiedenmann B, et al. Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in hilar cholangiocarcinoma. Ann Surg Oncol. 2008;15:791–9.PubMedCrossRef
43.
Zurück zum Zitat Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol. 2003;25:77–81.PubMed Kristiansen G, Yu Y, Schlüns K, Sers C, Dietel M, Petersen I. Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol. 2003;25:77–81.PubMed
44.
Zurück zum Zitat Walgenbach-Bruenagel G, Tolba RH, Varnai AD, Bollmann M, Hirner A, Walgenbach KJ. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40. Eur Surg Res. 2006;38:438–44.PubMedCrossRef Walgenbach-Bruenagel G, Tolba RH, Varnai AD, Bollmann M, Hirner A, Walgenbach KJ. Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40. Eur Surg Res. 2006;38:438–44.PubMedCrossRef
45.
Zurück zum Zitat Jackson DG. Lymphatic markers, tumour lymphangiogenesis and lymph node metastasis. Cancer Treat Res. 2007;135:39–53.PubMedCrossRef Jackson DG. Lymphatic markers, tumour lymphangiogenesis and lymph node metastasis. Cancer Treat Res. 2007;135:39–53.PubMedCrossRef
46.
Zurück zum Zitat Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.PubMedCrossRef Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.PubMedCrossRef
47.
Metadaten
Titel
Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma
verfasst von
Wenjun Wang
Zhu-lin Yang
Jie-qiong Liu
Song Jiang
Xiong-ying Miao
Publikationsdatum
01.02.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0260-8

Weitere Artikel der Ausgabe 1/2012

Tumor Biology 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.